A startup, NeuroKaire, is using blood samples to determine how an individual's brain will respond to different antidepressants and is developing a new form of precision medicine. The company's approach involves generating patient-specific neurons from a blood sample, exposing them to different drugs and analyzing them for accuracy. The results are then delivered to physicians as a treatment guidance report. The startup aims to help the more than 20 million adults in the US who experience depression every year.